Therapy for myeloproliferative neoplasms: when, which agent, and how?

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Myeloproliferative neoplasms (MPNs) present significant symptom burdens, complications, and risks of leukemia progression.
• Recent diagnostic and prognostic advancements have driven the development of targeted MPN therapies.
• Ruxolitinib has demonstrated efficacy in managing myelofibrosis (MF) symptoms, splenomegaly, and quality of life.

Purpose of the Study:

• To review the evolving data and role of JAK inhibition in managing MPNs.
• To discuss current and investigational JAK inhibitors for MF and polycythemia vera (PV).
• To highlight the expanding clinical applications of JAK2 inhibition.

Main Methods:

• Review of current clinical trial data and therapeutic strategies for MPNs.
• Analysis of the efficacy and safety profiles of existing and emerging JAK inhibitors.
• Exploration of combination therapies and novel pathway targets in MPN treatment.

Main Results:

• JAK inhibitors like ruxolitinib have improved outcomes in myelofibrosis.
• Ongoing trials investigate new JAK inhibitors (pacritinib, momelotinib) for MF and anemia.
• Phase 3 trials are evaluating frontline and second-line therapies for polycythemia vera, including JAK inhibitors.

Conclusions:

• JAK inhibition is a cornerstone in MPN management, offering symptomatic relief and disease control.
• The therapeutic landscape for MPNs is rapidly evolving with new agents and combination strategies.
• Continued research into JAK inhibitors and novel pathways promises further improvements in patient care for MPNs.